Skip to Content

Denosumab

In the US, Denosumab (denosumab systemic) is a member of the drug class miscellaneous bone resorption inhibitors and is used to treat Giant Cell Tumor of Bone, Hypercalcemia of Malignancy, Osteolytic Bone Metastases of Solid Tumors and Osteoporosis.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

M05BX04

CAS registry number (Chemical Abstracts Service)

0615258-40-7

Chemical Formula

C6404-H9908-N1724-O2004-S50

Therapeutic Categories

Treatment of osteoporosis

Monoclonal antibody

Chemical Name

Immunoglobulin G2, anti-(human tumor necrosis factor ligand superfamily member 11 (human osteoclast differentiation factor)) (human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer (WHO )

Foreign Names

  • Denosumabum (Latin)
  • Denosumab (German)
  • Dénosumab (French)
  • Denosumab (Spanish)

Generic Names

Brand Names

  • Pralia
    Daiichi Sankyo, Japan
  • Prolia
    Amgen, Australia; Amgen, Belgium; Amgen, Canada; Amgen, Czech Republic; Amgen, Germany; Amgen, Denmark; Amgen, Egypt; Amgen, Spain; Amgen, Finland; Amgen, France; Amgen, United Kingdom; Amgen, Georgia; Amgen, Greece; Amgen, Hungary; Amgen, Lithuania; Amgen, Latvia; Amgen, Norway; Amgen, Portugal; Amgen, Romania; Amgen, Serbia; Amgen, Sweden; Amgen, Slovakia; Amgen, United States; Amgen Austria, Austria; Amgen Dompè, Italy; Amgen Europa, Israel; Amgen Europe, Croatia (Hrvatska); Amgen Europe, Netherlands; Amgen Europe, Poland; Amgen Ltd., Ireland; Amgen Mexico, Mexico; Amgen Switzerland, Switzerland; GlaxoSmithKline, Chile; GlaxoSmithKline, Colombia; GlaxoSmithKline, Costa Rica; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Panama; GlaxoSmithKline, Peru; GlaxoSmithKline, Philippines; GlaxoSmithKline, Singapore; GlaxoSmithKline, Thailand; Wellcome Limited, Bosnia & Herzegowina; Amgen, Iceland
  • Ranmark
    Daiichi Sankyo, Japan
  • Xgeva
    Amgen, Belgium; Amgen, Canada; Amgen, Denmark; Amgen, Egypt; Amgen, Spain; Amgen, Finland; Amgen, United Kingdom; Amgen, Georgia; Amgen, Greece; Amgen, Hungary; Amgen, Lithuania; Amgen, Latvia; Amgen, Norway; Amgen, Portugal; Amgen, Romania; Amgen, Slovakia; Amgen, United States; Amgen Dompè, Italy; Amgen Europa, Israel; Amgen Europe, Croatia (Hrvatska); Amgen Europe, Netherlands; Amgen Europe, Poland; Amgen Ltd., Ireland; Amgen Mexico, Mexico; GlaxoSmithKline, Argentina; GlaxoSmithKline, Chile; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Philippines; GlaxoSmithKline, Singapore; Wellcome Limited, Bosnia & Herzegowina
  • XGEVA
    Amgen, Germany; Amgen, France; Amgen, Sweden; Amgen Europe, Austria; Amgen Switzerland, Switzerland

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide